Discover how Adobe Express's "Catch Feelings, Not Features" campaign transformed influencer marketing by focusing on ...

By hour two James wasn't the only one chafing at yet another training exercise in Malta.

The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

The ⁠Food and Drug ⁠Administration proposed excluding the active ingredients in Novo Nordisk ‌and Eli Lilly's blockbuster obesity and diabetes medications from the ⁠list ⁠of drugs that outsourcing ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

Replace the legacy repo-local config and storage assumptions with a two-scope state model: user_state_dir for user-level CE state and per-project durable storage repo_state_dir for repo-local CE ...

Replace the single-voice document-review skill with a multi-persona review pipeline that dispatches specialized reviewer agents in parallel. Two always-on personas (coherence, feasibility) run on ...

Drugmaker Eli Lilly says some copycat versions of its GLP-1 medications pose unique safety concerns — here’s what you need to know. A new study funded by Eli Lilly found that mixing compounded ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...

As GLP-1s remain popular across the U.S., the Food and Drug Administration says it’s now prepared to rein in a fast-growing corner of the market: compounding pharmacies and telehealth companies that ...